非酒精性脂肪性肝病的诊断与治疗进展

Advances in diagnosis and treatment of nonalcoholic fatty liver disease

非酒精性脂肪性肝病（NAFLD）是肥胖症、糖尿病、代谢综合征患者最为常见的肝脏疾病.代谢综合征是NAFLD的严重类型非酒精性脂肪性肝炎的重要预测指标,而糖尿病是NASH患者并发肝硬化和肝细胞癌的危险因素.随着肥胖症和糖尿病全球化的流行趋势,NAFLD已成为世界性的公共卫生问题.NAFLD不仅是肝病残疾和死亡的重要原因之一,还与糖尿病和心血管疾病的高发有关.NAFLD的有效防治可望显著减少肝病和心血管疾病负担.为此,本文介绍NAFLD诊断和防治方面的最新进展.

Nonalcoholic fatty liver disease （NAFLD） is the most common liver disease seen in patients with obesity,diabetes,and metabolic syndrome.Metabolic syndrome is an important predictor of the severe form of NAFLD,nonalcoholic steatohepatitis （NASH）,and NASH patients with diabetes have an increased risk of liver cirrhosis and hepatocellular carcinoma.With the prevalence of obesity and diabetes around the world,NAFLD has become a global public health problem.NAFLD is not only one of the most important causes of liver-related disability and mortality,but also associated with the increasing incidence of diabetes and cardiovascular disease.The effective prevention and treatment of NAFLD is expected to reduce the burden of liver disease and cardiovascular disease.Therefore,this article overviews the advances in the diagnosis,prevention,and treatment of NAFLD.